Optipharm Co Ltd
153710
Company Profile
Business description
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.
Contact
6, 63 Osong, Hwaseong-eup
Heungduk-gu
Chungcheongbuk-do
Cheongju
KORT: +82 432497500
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
81
Stocks News & Analysis
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks
ASX data center player expands pipeline but questions remain
Questions surround Australia’s largest data center developer and its growing pipeline.
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 77.80 | 0.88% |
| CAC 40 | 8,183.34 | 5.53 | -0.07% |
| DAX 40 | 25,104.70 | 12.45 | 0.05% |
| Dow JONES (US) | 50,958.97 | 290.00 | 0.57% |
| FTSE 100 | 10,409.28 | 16.68 | -0.16% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 26,943.26 | 25.79 | 0.10% |
| Nikkei 225 | 66,329.50 | 1,636.38 | 2.53% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,575.16 | 11.53 | 0.15% |
| S&P/ASX 200 | 8,731.70 | 73.10 | 0.84% |
| SSE Composite Index | 4,068.57 | 30.07 | -0.73% |